Midkine as a novel target for antibody therapy in osteosarcoma.
Osteosarcoma is a malignant tumor with poor prognosis, and lack of accurate prognostic factors is one of the reasons that make this tumor difficult to cure. The heparin-binding growth factor, midkine is involved in generation and progression of many types of tumors. However, the relationship between midkine and osteosarcoma has been unclear. We show here that midkine is overexpressed in osteosarcoma and the level of midkine expression is correlated with prognosis (P<0.05; log-rank test). Treatment with functional antibodies against midkine suppresses growth of osteosarcoma cell lines, 9N2, 3N1, Saos-2, and NOS-1, to 25-65% of untreated controls. Our results suggest that midkine is useful as a prognostic marker, and is a candidate therapeutic target for osetosarcomas.
Maehara
Hiroki
H
Department of Orthopedics, University of the Ryukyus Faculty of Medicine, 207 Uehara, Nishihara, Okinawa 903-0215, Japan.
Kaname
Tadashi
T
Yanagi
Kumiko
K
Hanzawa
Hiroaki
H
Owan
Ichiro
I
Kinjou
Takao
T
Kadomatsu
Kenji
K
Ikematsu
Shinya
S
Iwamasa
Teruo
T
Kanaya
Fuminori
F
Naritomi
Kenji
K
D000293:Adolescent; D000328:Adult; D000906:Antibodies / Q000737:chemistry*; D001859:Bone Neoplasms / Q000628:therapy*; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002648:Child; D016207:Cytokines / Q000737:chemistry* / Q000494:pharmacology*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D007167:Immunotherapy / Q000379:methods*; D000078792:Midkine; D012516:Osteosarcoma / Q000628:therapy*; D011379:Prognosis; D012189:Retrospective Studies
D000906:Antibodies; D016207:Cytokines; D000078792:Midkine